DK1289527T3 - (+)-alfa.(2,3-dimethoxyphenyl)-1-(2-(4-fluorphenyl)-ethyl)-4-piperodonmethanol eller dets prolægemiddel til behandling af demens eller kognitiv svækkelse - Google Patents

(+)-alfa.(2,3-dimethoxyphenyl)-1-(2-(4-fluorphenyl)-ethyl)-4-piperodonmethanol eller dets prolægemiddel til behandling af demens eller kognitiv svækkelse

Info

Publication number
DK1289527T3
DK1289527T3 DK01939312T DK01939312T DK1289527T3 DK 1289527 T3 DK1289527 T3 DK 1289527T3 DK 01939312 T DK01939312 T DK 01939312T DK 01939312 T DK01939312 T DK 01939312T DK 1289527 T3 DK1289527 T3 DK 1289527T3
Authority
DK
Denmark
Prior art keywords
piperodone
dimethoxyphenyl
dementia
prodrug
fluorophenyl
Prior art date
Application number
DK01939312T
Other languages
English (en)
Inventor
Richard Scheyer
Stephen Sorensen
Janice Hitchcock
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of DK1289527T3 publication Critical patent/DK1289527T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
DK01939312T 2000-05-25 2001-05-23 (+)-alfa.(2,3-dimethoxyphenyl)-1-(2-(4-fluorphenyl)-ethyl)-4-piperodonmethanol eller dets prolægemiddel til behandling af demens eller kognitiv svækkelse DK1289527T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20694300P 2000-05-25 2000-05-25
PCT/US2001/016653 WO2001089498A2 (en) 2000-05-25 2001-05-23 USE OF (+)-α -(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL OR ITS PRODRUG IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND DOPAMINE INDUCED PSYCHOSIS

Publications (1)

Publication Number Publication Date
DK1289527T3 true DK1289527T3 (da) 2008-07-14

Family

ID=22768607

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01939312T DK1289527T3 (da) 2000-05-25 2001-05-23 (+)-alfa.(2,3-dimethoxyphenyl)-1-(2-(4-fluorphenyl)-ethyl)-4-piperodonmethanol eller dets prolægemiddel til behandling af demens eller kognitiv svækkelse

Country Status (20)

Country Link
US (3) US20020099076A1 (da)
EP (1) EP1289527B1 (da)
JP (1) JP2003535058A (da)
KR (1) KR100784655B1 (da)
CN (1) CN1436078A (da)
AR (1) AR029666A1 (da)
AT (1) ATE390134T1 (da)
AU (2) AU6484201A (da)
BR (1) BR0111102A (da)
CA (1) CA2410554C (da)
DE (1) DE60133385T2 (da)
DK (1) DK1289527T3 (da)
ES (1) ES2300333T3 (da)
IL (1) IL152908A0 (da)
MX (1) MXPA02011511A (da)
NO (1) NO20025630L (da)
NZ (1) NZ522659A (da)
PT (1) PT1289527E (da)
TW (1) TWI299001B (da)
WO (1) WO2001089498A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1534391T3 (da) 2002-07-19 2007-06-11 Biovitrum Ab Nye piperazinyl-pyrazinonderivater til behandling af 5-HT2A-recptor-relaterede forstyrrelser
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
ES2359725T3 (es) * 2004-09-30 2011-05-26 F. Hoffmann-La Roche Ag Composiciones y métodos para el tratamiento de trastornos cognitivos.
DE102006040278A1 (de) * 2006-08-21 2008-03-20 Technische Universität Dresden Arzneimittel zur Behandlung des Charles-Bonnet-Syndroms
CA2992728A1 (en) 2015-07-20 2017-01-26 Acadia Pharmaceuticals Inc. Methods for preparing n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2017172757A1 (en) * 2016-03-29 2017-10-05 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
US11464768B2 (en) 2016-12-20 2022-10-11 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021428A (en) * 1985-07-02 1991-06-04 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds for the prophylactic treatment of migraine
US4783471A (en) * 1985-07-02 1988-11-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine methanol derivatives and the uses thereof
US4912117A (en) * 1985-07-02 1990-03-27 Merrell Dow Pharmaceuticals Inc. Novel chemical compounds
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4877798A (en) * 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
DE3888340T2 (de) * 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
US5106855A (en) * 1989-12-20 1992-04-21 Merrell Dow Pharmaceuticals Inc. Method for the treatment of glaucoma
US6004980A (en) * 1990-06-01 1999-12-21 Merrell Pharmaceuticals, Inc. (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
JP2869512B2 (ja) * 1990-06-01 1999-03-10 メレルダウファーマスーティカルズ インコーポレイテッド （＋）―α―（２，３―ジメトキシフェニル）―１―［２―（４―フルオロフェニル）エチル］―４―ピペリジンメタノール
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
FR2738819B1 (fr) * 1995-09-14 1997-12-05 Sanofi Sa Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
WO1999020315A1 (en) * 1997-10-23 1999-04-29 The Research Foundation Of State University Of New York Methods of screening potential atypical antipsychotic drugs
ATE249830T1 (de) 1998-08-28 2003-10-15 Aventis Pharma Inc Die verwendung von r (+)- g(a)-(2,3- dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemethanol zur behandlung von obstruktive schlafapnoe
UA57859C2 (uk) * 1998-10-14 2003-07-15 Авентіс Фармасьютікалз Інк. СКЛАДНІ ЕФІРИ (+)-АЛЬФА-(2,3-ДИМЕТОКСИФЕНІЛ)-1-[2-(4-ФТОРФЕНІЛ)ЕТИЛ]-4-ПІПЕРИДИНМЕТАНОЛУ, СПОСІБ ЇХ ОТРИМАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, СПОСІБ ІНГІБУВАННЯ ДІЇ СЕРОТОНІНУ НА 5HT<sub>2A</sub> РЕЦЕПТОР, СПОСІБ ЛІКУВАННЯ
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same

Also Published As

Publication number Publication date
KR100784655B1 (ko) 2007-12-12
EP1289527A2 (en) 2003-03-12
EP1289527B1 (en) 2008-03-26
PT1289527E (pt) 2008-05-13
NO20025630D0 (no) 2002-11-22
JP2003535058A (ja) 2003-11-25
NO20025630L (no) 2003-01-24
BR0111102A (pt) 2003-03-11
US20020099076A1 (en) 2002-07-25
DE60133385T2 (de) 2009-04-23
ES2300333T3 (es) 2008-06-16
CA2410554C (en) 2009-02-03
IL152908A0 (en) 2003-06-24
AU2001264842B2 (en) 2005-01-27
US20040204457A1 (en) 2004-10-14
US20030036553A1 (en) 2003-02-20
AU6484201A (en) 2001-12-03
TWI299001B (en) 2008-07-21
PL359176A1 (en) 2004-08-23
WO2001089498A2 (en) 2001-11-29
ATE390134T1 (de) 2008-04-15
CA2410554A1 (en) 2001-11-29
WO2001089498A3 (en) 2002-05-10
AR029666A1 (es) 2003-07-10
KR20030034078A (ko) 2003-05-01
NZ522659A (en) 2004-06-25
CN1436078A (zh) 2003-08-13
DE60133385D1 (de) 2008-05-08
MXPA02011511A (es) 2003-04-25
US7132433B2 (en) 2006-11-07

Similar Documents

Publication Publication Date Title
DK1353917T3 (da) Ny fremgangsmåde til syntesen af 5-(4-fluorphenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrol-3-carboxylsyre phenylamid
DE60037350D1 (de) Vefahren zur Zusammenarbeit unterschiedlicher IP Telefon-Protokolle
DE60216823D1 (de) Zwischenprodukten für die Herstellung von Pyridazinon Aldose Reductase Inhibitoren.
DK1140331T3 (da) Fremgangsmåde til fremstilling af en integral asymmetrisk polyolefinmembran
IT1317741B1 (it) Metodo per la preparazione di 5-cianoftalide.
NO20053473D0 (no) Fremgangsmate for fremstilling av R,R (eller S,S) konfigurasjonen av glykopyrroniumstereoisomerer
DK1289527T3 (da) (+)-alfa.(2,3-dimethoxyphenyl)-1-(2-(4-fluorphenyl)-ethyl)-4-piperodonmethanol eller dets prolægemiddel til behandling af demens eller kognitiv svækkelse
DK1279665T3 (da) Fremgangsmåde til fremstilling af perindopril, analoge forbindelser og salte heraf ved anvendelse af 2,5-dioxo-oxazolidin-mellemforbindelser
IT1319251B1 (it) Metodo per la preparazione di 5-carbossiftalide.
IL175983A0 (en) Processes and intermediates for the preparation of (r) -??-(2,3 - dimethoxyphenyl) - 1 - [2 - (4-fluorophenyl) ethyl] - 4 - piperidine methanol
HK1097835A1 (en) Process for the preparation of 2-(n-alkyl)-3-(4-hydroxybenzoyl) benzofuran and its intermediates
NO20041200L (no) Fremgangsmate for fremstilling av citalopram.
DK1233961T3 (da) Fremgangsmåde til fremstilling af 5-(1-piperazinyl)-benzofuran-2-carboxamid ved overgangsmetal-katalyseret aminering
BG107046A (en) Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
DK1599433T3 (da) Fremgangsmåde til fremstilling af de enantiomere former af cis-konfigurerede 1,3-cyclohexandiolderivater
DK1373232T3 (da) Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner
EE200400098A (et) Meetod 2-(asendatud fenüül)-2-hüdroksüetüülkarbamaatide valmistamiseks, selleks vajalikud vaheühendid ning saadud karbamaatide polümorfsed vormid
DK1383763T3 (da) Fremgangsmåde til fremstilling af 2-(-5-(4-fluorphenyl)-3-pyridylmethylaminomethyl)-chroman
DK0915076T3 (da) Fremgangsmåde til fremstilling af trans-(R,R)-actinol
BR0116766B1 (pt) processo para a fabricaÇço de um suporte anelar com canal de refrigeraÇço de chapa soldado.
AU2003222435A1 (en) Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
ITRM20010309A0 (it) Procedimento per la produzione di composti perfluoro-organici mediante florurazione elettrochimica.
AU4595100A (en) ((e),3(r))-enantiomer of 4-(3-chloro -4-cyanophenyl) -1-(p- methylsulphonyl -phenylsulphonyl) -2-trifluoromethylbut -trans-3-en-ol
FR2797443B1 (fr) Procede de prepartion de quinoleine-5,8-diones
SI1192134T1 (sl) Postopki za pripravo (R)-alfa-(2,3-dimetoksifenil)-1-2-(4-fluorofenil) etil)-4-piperidinmetanola